|
|
News for Healthier Living
Monoclonal Antibody Targeting Interleukin-6 Achieves Sustained Reductions in Inflammation Biomarkers Through Six Months
Phase 2 TRANQUILITY trial results presented by Mount Sinai investigator support further evaluation of pacibekitug in cardiovascular disease
August 29, 2026
September 1 2026August 31 2026August 30 2026August 29 2026August 28 2026August 27 2026August 26 2026August 25 2026August 24 2026August 21 2026August 20 2026August 19 2026August 18 2026
|
|
|
|
|